Allergan Recalls Eye Treatments Amid Safety Concerns

Allergan PLC said it is recalling certain lots of eye-treatment ointments sold in the U.S. under the Refresh, Lacri-Lube and other brands amid concerns about patient safety.

In a news release Monday, Allergan said the recall is in response to a small number of customer complaints of a black particle, which potentially can be introduced into the product when the cap of the aluminum tube is unscrewed.

The company said complaints include 12 reports of a foreign body in the eye, two reports of eye irritation and two reports of product contamination.

Allergan said the company is contacting retailers and wholesalers who have been shipped the recalled product lots to initiate the recall.

Consumers with affected lots of Refresh, Lacri-Lube, Refresh P.M., FML and Belphamide are requested to stop using the products and return them to Allergan. Consumers also are urged to contact their physician or health-care provider about any problems related to use of the recalled products.

Actavis PLC completed its roughly $66 billion deal for the maker of wrinkle treatment Botox in March, forming one of the top 10 drug companies by sales. The combined Dublin-based pharmaceutical company renamed itself as Allergan in June.

Write to Tess Stynes at [e-mail]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

August 24, 2015 10:05 ET (14:05 GMT)

Copyright (c) 2015 Dow Jones & Company, Inc.